

Hypokalemic rhabdomyolysis: a rare manifestation of primary aldosteronism

A. ZAVATTO¹, A. CONCISTRÈ², C. MARINELLI², V. ZINGARETTI¹, I. UMBRO¹, F. FIACCO¹, F. TINTI¹, L. PETRAMALA², A.P. MITTERHOFER¹, C. LETIZIA²

¹Department of Clinical Medicine, Nephrology and Dialysis and ²Department of Internal Medicine and Medical Specialties, "Sapienza" University of Rome, Rome, Italy

Abstract. – Rhabdomyolysis is a rare presentation of hypokalemia, although muscle weakness is a well-known manifestation of hypokalemia. Primary aldosteronism is characterized by hypertension, suppressed plasma renin activity, increased aldosterone excretion and hypokalemia with metabolic alkalosis. Rhabdomyolysis is not common in primary aldosteronism.

We present here a 40-year-old woman presenting with rhabdomyolysis accompanied by severe hypokalemia as heralding symptom of primary aldosteronism.

Key Words:

Hypokalemia, Rhabdomyolysis, Primary aldosteronism.

Introduction

Primary aldosteronism (PA) was initially considered a rare disease affecting 1% of hypertensive patients. Studies published in the last years revealed that PA is the most frequent cause of secondary arterial hypertension¹. The main causes of PA included aldosterone producing adenoma (APA), unilateral and bilateral adrenal cortex hyperplasia (IHA), the familial types of the disease and aldosterone secreting adrenal carcinoma^{2,3}. APA and unilateral adrenal hyperplasia (UAH) are treated by adrenalectomy, whereas IHA is treated with aldosterone receptor antagonists⁴.

Patients with PA typically present hypertension, and the uncontrolled synthesis of aldosterone leads to increased sodium reabsorption, kaliuresis, varying degrees of hypokalemia and metabolic alkalosis. The hypokalemia is usually mild⁵. Nevertheless it could become extremely

severe and even life threatening. In particular serious complication of hypokalemia is the rhabdomyolysis⁶ which may be the first manifestation of the PA. At today few cases have been reported in the English literature⁷⁻²⁶.

Here, we present a new case of PA presenting with rhabdomyolysis due to severe hypokalemia.

Case Report

A 40-year-old woman was referred to our Hospital with severe myalgia involving legs, stiffness and muscle weakness of the upper arms, lasting 4 days. She had a previous history of arterial hypertension diagnosed two years previously and treated with irbesartan plus hydrochlorothiazide. The family history was negative for PA and history of hypokalemic disorder. She did not take liquorice and herbs.

At the Emergency Department, laboratory findings showed severe hypokalemia (K^+ 1.64 mEq/L; normal range 3.4-5.5 mEq/L), metabolic alkalosis (pH 7.58, pCO_2 54 mmHg, HCO_3^- 44.3 mmol/L), increase of creatine phosphokinase (CPK) 12.085 U/L (normal range 90-140 U/L) and myoglobinemia 1714 ng/ml (normal range: 25-58 ng/ml). Based on these data and clinical picture hypokalemic rhabdomyolysis was diagnosed. Fluid intravenous (IV) hydration and IV potassium supplementation were administered, and the patient was referred to Department of Clinical Medicine, Nephrology and Dialysis. At admission, her physical examination was unremarkable, apart from extreme muscular weakness, especially of the arms and the legs, rendering elevation above the shoulder level almost impossible. No edema or rash was detected. Blood pressure was 130/80 mmHg. Electrocardiogram revealed flattered T waves and prolongation of QT interval (QTc 597

msec). The chest x-ray was normal, and 2-dimensional Doppler echocardiogram revealed a mitral prolapse.

Laboratory findings confirmed severe hypokalemia (1.66 mEq/L), extreme elevation of

the serum CPK level (9122 U/L), high serum myoglobin level (911 ng/ml) and metabolic alkalosis (Table I). The patient was treated with IV administration of potassium rich solutions followed by reduction of hypokalemia and reversal

Table I. Laboratory data at admission and follow-up.

Variables	At admission	3 weeks during recovery	At discharge	6 months after recovery
Blood chemistry				
WBC ($\times 10^3/\mu\text{L}$)	6.4	6.5	4.98	4.72
RBC ($\times 10^3/\mu\text{L}$)	441	420	413	428
HB (g/dL)	12.7	12.1	11.9	12.1
HCT (%)	36	34.4	33.6	39
PLT ($\times 10^3/\mu\text{L}$)	26.3	25.2	19.6	22.1
BUN (mg/dL)	8	7	6.3	6.4
CREAT (mg/dL)	0.6	0.5	0.9	0.8
GOT (IU/L)	262	178	25	30
GPT (IU/L)	118	114	49	50
LDH (IU/L)	445	426	204	200
γ GT (IU/L)	39	30	25	24
T-BIL (mg/dL)	0.48	0.46	0.52	0.48
Na (mEq/L)	142	141	138	139
K (mEq/L)	1.66	2.76	4.2	4.1
Cl (mEq/L)	90	101	102	103
Ca (mg/dL)	9.2	8.5	9.3	9.8
P (mg/dL)	2.3	2.9	3.1	3.5
Glucose (mg/dL)	84	81	74	85
T-chol (mg/dL)	128	-	158	168
TG (mg/dL)	117	-	127	81
HDL-C (mg/dL)	48	-	51	65
CPK (U/L)	9122	5273	124	77
CPK-MB (U/L)	16	10	4.1	0.8
Myoglobin (ng/ml)	911	631	55	14.6
Alb (g/dl)	4	4.2	4.1	4.2
Uric Acid (mg/dL)	1.6	1.8	1.7	2.5
Arterial blood gas analysis				
pH	7.58	7.48	7.42	7.4
pO ₂ (mmHg)	61	69	88	92
pCO ₂ (mmHg)	52	47	33	32
HCO ₃ ⁻ (mmHg)	48.8	35	21.4	20.4
B.E. (mmHg)	23.7	10.1	2.4	1.1
Urine excretion				
Ca ⁺ (mg/24h)	242	238	201	—
P ⁺ (mg/24h)	837	821	805	—
K ⁺ (mEq/24h)	88	53	35	—
Cl ⁻ (mg/24h)	161	158	140	—
Na ⁺ (mEq/24h)	190	147	130	—
Mg ⁺ (mg/24h)	141	138	132	—

Table II. Endocrine tests results.

Hormones	At diagnosis	Follow up with eplerenone treatment	Normal range
Plasma renin activity (PRA) (ng/ml/h)	0.2	0.2	(0.3-2.7)
Plasma aldosterone (PAC) (ng/dl)	28.67	58.8	(3-16)
Plasma cortisol (PC) (µl/dl)	524.9	628.6	(266-720)
Plasma ACTH (pg/ml)	58.8	48.3	(10-90)
PAC/PRA ratio (ng/dl:ng/ml/h)	143	294	(< 30)
Urinary excretion			
Urinary free cortisol (UFC) (nmol/24 h)	233.5	185.9	(38-208)
Urinary aldosterone (UA) (µg/24 h)	39.8	55.2	(2,84-34)

of muscular weakness (Table I). The combination of hypokalemia, hyperkaluria, metabolic alkalosis with hypertension raised the suspicion of inappropriate secretion of mineralcorticoids, and, we performed hormonal analysis.

Plasma renin activity (PRA) was suppressed (0.20 ng/ml/h) with an increase of plasma (PAC) and urine aldosterone (UA) concentrations (28.67 ng/dl and 39.8 ng/24h, respectively), with a high PAC/PRA ratio (143 ng/dl:ng/ml/h) (Table II).

Suspecting an APA, we conducted further evaluation. Abdominal magnetic resonance (MR) showed multiple nodules in the bilaterally adrenal glands (Figure 1A). Subsequently, adrenal venous sampling (AVS) was performed (Figure 1B). Proper placement of the catheter tip was confirmed using a small amount of

contrast medium. The PAC levels in the left and the right adrenal veins were 87.35 ng/dl and 100.62 ng/dl, respectively. Based on the plasma cortisol (PC) levels in the left and the right adrenal veins (554 nmol/l and 577.8 nmol/l, respectively), we consider that the catheters had been correctly inserted into the adrenal vein.

All these results suggest no lateralization of PAC from the adrenal glands and excluding the possibility of surgical procedure in this case. The patient was treated with an anti-aldosterone receptors drugs (spironolactone) and oral potassium supplement with restoration of electrolytes balance and good control of blood pressure (130/80 mmHg) (Table I).

Six months after discharge the patient was asymptomatic, and followed in our Specialized




Figure 1. Abdominal magnetic resonance scan (A) showed a bilateral adrenal nodules; (B) selective catheterism of adrenal veins for adrenal venous sampling (AVS).

Center of Secondary Hypertension. Physical examination was normal, her average blood pressure was 130/85 mmHg, and 24-h-ambulatory blood pressure monitoring (ABPM) showed mean normal values (125/80 mmHg) with dipping-profile. Electrocardiogram was normal. General laboratory test did not reveal any remarkable abnormalities, with normalization of potassium, CPK and myoglobinemia values (Table I). The patient continued receiving treatment with an anti-aldosterone receptors drug (eplerenone).

Discussion

Rhabdomyolysis is the destruction of a significant amount of striated muscle, leading to disruptions in fluid balance, electrolytes and renal function. Diagnosis is typically made through the timely determination of the serum CPK in a patient with a suggestive history or clinical features^{27,28}. The most frequent symptoms of rhabdomyolysis are fatigue, weakness, muscular pain and swelling, although it is possible that some patients are completely asymptomatic²⁹. The common and well known causes of rhabdomyolysis include excessive physical exertion, trauma, alcoholism, drugs (such as statins), liquorice, certain genetic disorders and electrolyte disorders such as hypokalemia.

The presented patient showed severe hypokalemia of 1.6 mEq/l associated with generalized weakness and rhabdomyolysis. Severe hypokalemia was attributed to PA due to bilateral nodular adrenal glands. At today few complete cases have been reported of PA excess being related to hypokalemic rhabdomyolysis in the English literature⁷⁻²⁶ (Table III).

The severity of neuromuscular disorders, in the rhabdomyolysis, tends to be proportionate to the rate at which hypokalemia develops. Muscle destruction due to rhabdomyolysis causes the release of large amounts of potassium in the circulation. Consequently, where the clinical syndrome of hypokalemia and rhabdomyolysis develops, the absolute concentration of potassium is far below the normal limits. Large amounts of potassium supplementation are necessary associated with generous intravenous hydration²⁹. Frank rhabdomyolysis usually occurs only when serum potassium values are below 2.0 mEq/L³⁰.

PA is characterized by the autonomous overproduction of aldosterone by the adrenal glands, and only a minority of patients (less than one half) presented with hypokalemia; the majority of patients showing normokalemic hypertension, especially in IHA^{1,31}.

Potassium is predominantly an intracellular cation, as only 2% of the total body potassium can be found in the extracellular space. The homeostatic serum potassium concentration is maintained by the terminal nephron segments of the kidney. Insulin, β -adrenergic agonists, aldosterone and a change in blood pH may all independently affect the serum potassium levels³².

Severe hypokalemia might play an important role in muscle damage, secondary to: (1) contraction of capillaries with reduction in muscle blood supply and resulting in lysing muscle cells; (2) suppression of synthesis and storage of glycogen, and (3) deranged ion transport across the cell membrane^{33,34}.

Conclusions

We report an unusual case of PA due to multiple bilateral nodules, presenting with rhabdomyolysis secondary to severe hypokalemia and not associated with the development of acute kidney injury. The prompt volume expansion and correction of hypokalemia resolved the rhabdomyolysis. It is possible that metabolic alkalosis associated to hypokalemia may have contributed to the good outcome of kidney function.

This case underlines the risk of hypokalemia-induced rhabdomyolysis in patients with PA, in particular when diuretic treatment for hypertension is associated.

Conflict of Interest

The Authors declare that they have no conflict of interests.

References

- 1) ROSSI GP, BERNINI G, CALIUMI C, DESIDERI G, FABRIS B, FERRI C, GANZAROLI C, GIACCHETTI G, LETIZIA C, MACCARIO M, MALLAMACI F, MANNELLI M, MATTARELLO MJ, MORETTI A, PALUMBO G, PARENTI G, PORTERI E, SEMPLICINI A, RIZZONI D, ROSSI E, BOSCARO M, PESSINA AC, MANTERO F. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. *J Am Coll Cardiol* 2006; 48: 2293-2300.

Table III. Clinical and main laboratory characteristics of patients with rhabdomyolysis and primary aldosteronism including the present case.

No. (years)	Age (years)	Sex (m/f)	BP at Anti-HTN admission (mmHg)	Muscular weakness	Renal failure	K+ (mmol/l)	Na (mmol/L)	Metabolic alkalosis	CK (U/L)	PAC (ng/dL)	ARR (ng/dL: ng/mL/h)	Image investigation	AVS	Subtype	References
1	68	M	HCT UN	Yes	No	0.6	138	UN	3.250	34.7	UN	UN	UN	UN	Crawhall JC, et al. 1976 ²⁰
2	49	M	HCT 150/100	Yes	Yes	2.5	142	Yes	12.030	81	300	UN	Yes	Adenoma	Dominic JA et al. 1978 ¹⁶
3	55	M	Furosemide UN	Yes	No	1.8	141	Yes	2.000	33.3	UN	UN	UN	Adenoma	Atsumi T, et al. 1979 ²¹
4	60	M	Metoprolol, 185/100	Yes	UN	1.4	144	UN	36.000	22	0.23	CT	UN	UN	Schady W, et al. 1981 ²²
5	32	F	B-blocker, 170/110 HCT	Yes	No	2.0	UN	UN	10.000	60	58	CT, Scintigraphy	UN	Adenoma	Mahdyoon H et al. 1990 ¹⁵
6	70	M	B-blocker, UN Calcium channel blocker	Yes	Yes	1.8	138	UN	2.800	117.2	UN	CT	No	Adenoma	Chow CP, et al. 1997 ¹⁴
7	30	F	Fosinopril, 170/100 Calcium channel blocker, HCT, Furosemide	Yes	No	1.3	146	Yes	1.751	97.1	UN	Ultrasound, CT	UN	Adenoma	Ozgür B et al. 2002 ¹³
8	44	F	ACEI, 160/90 Verapamil	Yes	No	1.2	137	UN	6.133	46	153.3	CT	UN	Adenoma	Ka ifo lu T, et al. 2005 ²³
9	36	F	Atenolol, 152/108 Chlorthalidone	Yes	Yes	2.2	UN	Yes	2.860	17.4	87	CT	UN	Adenoma	Petidis K, et al. 2007 ¹⁸
10	50	F	Amlodipine 180/70	Yes	No	1.95	UN	UN	9.546	62.2	UN	Ultrasound, CT	UN	Nodular hyperplasia	Gonerska -Szadkowska A, et al. 2007 ²⁴
11	28	F	None 174/111	Yes	No	1.8	143	Yes	12.147	19.8	141	CT	UN	Adenoma	Chuang T, et al. 2008 ²⁵
12	42	F	None 166/108	Yes	UN	1.3	138	Yes	21.000	96.6	>241.5	CT	UN	Adenoma	Martinez JJ et al. 2009 ¹⁰
13	14	F	None 160/120	No	UN	1.7	145	Yes	3.375	29.5	147.5	CT,MR	UN	Adenoma	Karagüzel G, et al. 2009 ⁹
14	55	M	Amlodipine, 138/68 Valsartan, HCT	Yes	No	1.4	152	Yes	15.760	26.6	266	CT	UN	Adenoma	Goto A, et al. 2009 ¹²
15	73	M	Amlodipine 140/80	Yes	No	1.6	UN	Yes	7.463	49.8	71.14	CT	UN	Unilateral hyperplasia	Kotsaftis P, et al. 2009 ¹¹
16	49	F	Amlodipine, 130/80 Valsartan	Yes	No	1.8	UN	Yes	1.753	64.89	67.7	CT	UN	Bilateral adenomas	Tsai WT, et al. 2012 ⁸

Table continued

Table III. (Continued). Clinical and main laboratory characteristics of patients with rhabdomyolysis and primary aldosteronism including the present case.

No.	Age (years)	Sex (m/f)	Anti-HTN drugs	BP at admission (mmHg)	Muscular weakness	Renal failure	K ⁺ (mmol/l)	Na (mmol/L)	Metabolic alkalosis	CK (U/L)	PAC (ng/dL)	ARR (ng/dL: ng/mL/h)	Image investigation	AVS	Subtype	References
17	45	F	Nifedipine, Captopril	143/80	Yes	No	1.38	142	No	4.907	63.93	76.12	CT	UN	Adenoma	Wen Z. et al. 2013 ¹⁷
18	44	F	UN	UN	Yes	No	1.98	146	Yes	8.531	44.97	642.43	CT	UN	Adenoma	Wen Z. et al. 2013 ¹⁷
19	42	F	Nifedipine, Atenolol, Losartan	160/100	Yes	No	2.0	145	Yes	11.347	22.6	113	CT	UN	Adenoma	Cooray MS. et al. 2013 ⁷
20	60	M	None	UN	Yes	No	1.7	142	UN	1.522	UN	UN	MR	Yes	Adenoma	Finsterer J et al. 2013 ¹⁹
21	38	M	Metoprolol, Felodipine	165/102	Yes	No	2.8	145	No	2.974	13	130	CT	No	Adenoma	Yao B et al. 2015 ²⁶
22	40	F	Irbesartan, HCT	130/80	Yes	No	1.66	142	Yes	9.122	28.67	143	MR	Yes	Bilateral nodular hyperplasia	Present Case

Abbreviations: ACEI = angiotensin-converting enzyme inhibitor; ARR = aldosterone to renin ratio; AVS = adrenal venous sampling; BP = blood pressure; CK = creatine kinase; CT = computed tomography; F = female; HCT = hydrochlorothiazide; HTN = hypertension; M = male; MR = magnetic resonance; UN = unavailable; PAC = plasma aldosterone concentration

- MORAITIS A, STRATAKIS C. Adrenocortical causes of hypertension. *Int J Hypertens* 2011; 2011: 624691.
- ROSSI GP, SECCIA TM, PESSINA AC. Primary aldosteronism: part II: subtype differentiation and treatment. *J Nephrol* 2008; 21: 455-462.
- YOUNG WF JR. Minireview: primary aldosteronism--changing concepts in diagnosis and treatment. *Endocrinology* 2003; 144: 2208-2213.
- MULATERO P, STOWASSER M, LOH KC, FARDELLA CE, GORDON RD, MOSSO L, GOMEZ-SANCHEZ CE, VEGLIO F, YOUNG WF JR. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. *J Clin Endocrinol Metab* 2004; 89: 1045-1050.
- De WOLFF JF RHABDOMYOLYSIS. *Br J Hosp Med (Lond)* 2012; 73: C30-32.
- COORAY MS, BULUGAHAPITIYA US, PEIRIS DN. Rhabdomyolysis: A rare presentation of aldosterone-producing adenoma. *Indian J Endocrinol Metab* 2013; 17(Suppl 1): S237-239.
- TSAI WT, CHEN YL, YANG WS, LIN HD, CHIEN CC, LIN CL. Primary aldosteronism associated with severe hypokalemic rhabdomyolysis. *Hormones (Athens)* 2012; 11: 505-506.
- KARAGÜZEL G, BAHAT E, IMAMO LU M, AHMETO LU A, YILDIZ K, OKTEN A. An unusual case of an aldosterone-producing adrenocortical adenoma presenting with rhabdomyolysis. *J Pediatr Endocrinol Metab* 2009; 22: 1087-1090.
- MARTÍNEZ JJ, OLIVEIRA CL, MENESES AL, RODRÍGUEZ SA, CORRALES PP, LÓPEZ AH, ROMERO FB. Rhabdomyolysis due to primary hyperaldosteronism. *Endocrinol Nutr* 2009; 56: 431-434.
- KOTSaftis P, SAVOPOULOS C, AGAPAKIS D, NTAIOS G, TZIOUFA V, PAPADOPOULOS V, FAHANTIDIS E, HATZITOLIOS A. Hypokalemia induced myopathy as first manifestation of primary hyperaldosteronism--an elderly patient with unilateral adrenal hyperplasia: a case report. *Cases J* 2009; 2: 6813.
- GOTO A, TAKAHASHI Y, KISHIMOTO M, MINOWADA S, AIBE H, HASUO K, KAJIO H, NODA M. Primary aldosteronism associated with severe rhabdomyolysis due to profound hypokalemia. *Intern Med* 2009; 48: 219-223.
- OZGÜR B, KÜRSAT S. Hypokalemic rhabdomyolysis aggravated by diuretics complicating Conn's syndrome without acute renal failure. *Clin Nephrol* 2002; 57: 89-91.
- CHOW CP, SYMONDS CJ, ZOCHODNE DW. Hyperglycemia, lumbar plexopathy and hypokalemic rhabdomyolysis complicating Conn's syndrome. *Can J Neurol Sci* 1997; 24: 67-69.
- MAHDYOON H, MERMIGES DN, WISGERHOF M. Conn's syndrome with rhabdomyolysis mimicking deep vein thrombophlebitis. *South Med J* 1990; 83: 346-347.
- DOMINIC JA, KOCH M, GUTHRIE GP JR, GALLA JH. Primary aldosteronism presenting as myoglobinuric acute renal failure. *Arch Intern Med* 1978; 138: 1433-1434.

- 17) WEN Z, CHUANWEI L, CHUNYU Z, HUI H, WEIMIN L. Rhabdomyolysis presenting with severe hypokalemia in hypertensive patients: a case series. *BMC Res Notes* 2013; 6: 155.
- 18) PETIDIS K, DOUMA S, ASLANIDIS S, PAPAETHIMIOU P, KARTALI N, ZAMBOULIS C. Hypertension associated with rhabdomyolysis. *J Clin Hypertens (Greenwich)* 2007; 9: 60-62.
- 19) FINSTERER J, LÄSSER S. Severe hypokalemic paralysis as a manifestation of a mitochondrial disorder. *Tohoku J Exp Med* 2013; 231: 9-12.
- 20) CRAWHALL JC, TOLIS G, ROY D. Elevation of serum creatine kinase in severe hypokalemic hyperaldosteronism. *Clin Biochem* 1976; 9: 237-240.
- 21) ATSUMI T, ISHIKAWA S, MIYATAKE T, YOSHIDA M. Myopathy and primary aldosteronism: electronmicroscopic study. *Neurology* 1979; 29: 1348-1353.
- 22) SCHADY W, YUILL GM. Myopathy and primary hyperaldosteronism. *Neurology* 1981; 31: 225-226.
- 23) KA IFO LU T, KORKMAZ C, PA AO LU O. Conn's syndrome (primary hyperaldosteronism) simulating polymyositis. *Rheumatol Int* 2005; 25: 133-134.
- 24) GONERSKA-SZADKOWSKA A, WITTYCH-DLUGOSZ J, MAKAREWICZ J, SZMIDT M, LEWINSKI A. Rhabdomyolysis following severe hypokalemia caused by Conn's syndrome. *Arch Med Sci* 2007; 3: 274-277.
- 25) CHUANG T, WANG C, TSENG B, HSU Y, TSAI J, HSU B, ET AL. Conn's syndrome with an unusual presentation of rhabdomyolysis secondary to severe hypokalemia. *Tzu Chi Med J* 2008; 20: 327-331.
- 26) YAO B, QIN Z, TAN Y, HE Y, YAN J, LIANG Q, XU W, WENG J. *AACE Clin Case Rep* 2015; 1: e21-e27.
- 27) KNOCHEL JP. Mechanisms of rhabdomyolysis. *Curr Opin Rheumatol* 1993; 5: 725-731.
- 28) VANHOLDER R, SEVER MS, EREK E, LAMEIRE N. Rhabdomyolysis. *J Am Soc Nephrol* 2000; 11: 1553-1561.
- 29) WARREN JD, BLUMBERGS PC, THOMPSON PD. Rhabdomyolysis: a review. *Muscle Nerve* 2002; 25: 332-347.
- 30) KNOCHEL JP, SCHLEIN EM. On the mechanism of rhabdomyolysis in potassium depletion. *J Clin Invest* 1972; 51: 1750-1758.
- 31) FUNDER JW, CAREY RM, FARDELLA C, GOMEZ-SANCHEZ CE, MANTERO F, STOWASSER M, YOUNG WF JR, MONTORI VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 2008; 93: 3266-3281.
- 32) BROWN MJ, BROWN DC, MURPHY MB. Hypokalemia from beta2-receptor stimulation by circulating epinephrine. *N Engl J Med* 1983; 309: 1414-1419.
- 33) ALLISON RC, BEDSOLE DL. The other medical causes of rhabdomyolysis. *Am J Med Sci* 2003; 326: 79-88.
- 34) KNOCHEL JP. Mechanisms of rhabdomyolysis. *Curr Opin Rheumatol* 1993; 5: 725-731.